Abstract Details

Title A Phase 1b/2a Study to Examine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-935 as an Adjunctive Therapy in Subjects with Developmental and/or Epileptic Encephalopathies

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P5 - (-)

Poster/Presentation
Number 266

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
PRESENTER	No disclosure on file
Asif M. Paker, MD, MPH	Dr. Paker has received personal compensation for serving as an employee of SwanBio Therapeutics.
	No disclosure on file
Deborah A. Lee, MD, PhD (AlaWai Neurology Consulting LLC)	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��